157 related articles for article (PubMed ID: 37708450)
21. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
22. Targeting the non-ATP-binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T-cell lymphoma (CTCL).
Zhang XH; Chen CH; Li H; Hsiang J; Wu X; Hu W; Horne D; Nam S; Shively J; Rosen ST
FEBS Lett; 2021 Oct; 595(20):2570-2592. PubMed ID: 34455585
[TBL] [Abstract][Full Text] [Related]
23. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
24. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
[TBL] [Abstract][Full Text] [Related]
25. ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2.
Zhu M; Liu Y; Lei P; Shi X; Tang W; Huang X; Pan X; Wang C; Ma W
Curr Cancer Drug Targets; 2022; 22(4):328-339. PubMed ID: 35220934
[TBL] [Abstract][Full Text] [Related]
26. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
[TBL] [Abstract][Full Text] [Related]
27. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways.
Suzuki H; Boki H; Kamijo H; Nakajima R; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S; Miyagaki T
J Invest Dermatol; 2020 Apr; 140(4):860-868.e3. PubMed ID: 31622598
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.
Wei T; Biskup E; Gjerdrum LM; Niazi O; Ødum N; Gniadecki R
Oncotarget; 2016 Jul; 7(30):48391-48400. PubMed ID: 27351221
[TBL] [Abstract][Full Text] [Related]
29. Reversible resistance to apoptosis in cutaneous T cell lymphoma.
Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC
Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582
[TBL] [Abstract][Full Text] [Related]
30. Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells.
Yang H; Tao Y; Zhang M; Ma P; Li L; Diao Q
Anticancer Drugs; 2019 Jan; 30(1):56-64. PubMed ID: 30198914
[TBL] [Abstract][Full Text] [Related]
31. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.
Verma NK; Davies AM; Long A; Kelleher D; Volkov Y
Cell Mol Biol Lett; 2010 Jun; 15(2):342-55. PubMed ID: 20213502
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.
Kamstrup MR; Biskup E; Manfè V; Savorani C; Liszewski W; Wirèn J; Specht L; Gniadecki R
Leuk Lymphoma; 2017 Jan; 58(1):171-178. PubMed ID: 27181628
[TBL] [Abstract][Full Text] [Related]
33. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
[TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
35. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
36. Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression.
Rishi L; Gahlot S; Kathania M; Majumdar S
Biochem Pharmacol; 2009 Jan; 77(1):30-45. PubMed ID: 18851957
[TBL] [Abstract][Full Text] [Related]
37. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.
Yu XX; Zhu MY; Wang JR; Li H; Hu P; Qing YJ; Wang XY; Wang HZ; Wang ZY; Xu JY; Guo QL; Hui H
Acta Pharmacol Sin; 2021 Feb; 42(2):290-300. PubMed ID: 32747719
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
[TBL] [Abstract][Full Text] [Related]
39. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
Manfè V; Biskup E; Rosbjerg A; Kamstrup M; Skov AG; Lerche CM; Lauenborg BT; Odum N; Gniadecki R
PLoS One; 2012; 7(1):e29541. PubMed ID: 22235305
[TBL] [Abstract][Full Text] [Related]
40. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
